Sequential Chemoimmunotherapy of Experimental Visceral Leishmaniasis Using a Single Low Dose of Liposomal Amphotericin B and a Novel DNA Vaccine Candidate
Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve treatment of complex manifestations of the disease. We evaluated a novel T-cell epitope enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard anti-leishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2020.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#7,468
of 15,579 outputs
Outputs of similar age
#96,629
of 280,054 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#91
of 248 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,579 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,054 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 248 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
